NCT00711204View on ClinicalTrials.gov

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2009

Conditions
Severe Alzheimer's Disease
Interventions
DRUG

Donepezil Hydrochloride (Aricept)

5mg (or 10mg) tablet, once daily, with a full glass of water.

Trial Locations (1)

43609

Kettlie Joseph Daniels, M.D. Inc., Toledo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00711204 - Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter